Clinical Trial Update: Neoadjuvant Anti-PD1 in HCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant anti-PD1 trial in hepatocellular carcinoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Dr Tan-to CHEUNG | Conditions: Hepatocellular Carcinoma, HCC | Phase 2 | Status: COMPLETED